Back to results
US 12,509,518 B2Granted
Methods and compositions for inhibiting CD32B expressing cells in IgG4-related diseases
AssigneeXencor, Inc.
InventorsDebra Zack, John H. Stone, Shiv Pillai, Paul Foster
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to immunoglobulins that bind FcγRIIb+ B cells and coengage CD19 on the cell's surface and an FcγRIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins for the treatment of an IgG4-related disease.
Claims12
A formulation for subcutaneous administration comprising an anti-CD19 antibody at a concentration of 100-250 mg/ml, an acetate buffer and proline, wherein the anti-CD19 antibody comprises,
- a heavy chain of SEQ ID NO:
- 9 and
- a light chain of SEQ ID NO:
- 7.
1 more element
A formulation for subcutaneous administration comprising:
- (a) 100-250 mg/ml of an anti-CD19 antibody;
- (b) 1-2.5 mg/mL Sodium acetate;
- (c) 1-2.5 mg/mL acetic acid;
- (d) 20-40 mg/mL proline;
- (e) 0.05-0.2 mg/mL Polysorbate-80;
- and
- wherein the anti-CD19 antibody comprises a light chain comprising SEQ ID NO:
- 7, and a heavy chain comprising SEQ ID NO:
- 9.
6 more elements
Dependencies are inferred from the claim text.